Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5841494 | 0.99 | FGFR3 (0.43) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL6985289 | 0.86 | SIGMAR1 (0.40) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5842442 | 0.85 | HTR7 (0.41) | SIGMAR1 | |
| SCHEMBL6984251 | 0.85 | HTR7 (0.41) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5840216 | 0.84 | HTR7 (0.41) | SIGMAR1 | |
| SCHEMBL6986839 | 0.82 | ALDH1A1 (0.43) | SIGMAR1 | |
| SCHEMBL6986270 | 0.81 | SLC29A1 (0.41) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5842572 | 0.80 | MEN1 (0.40) | SIGMAR1 | |
| SCHEMBL5842277 | 0.78 | SLC29A1 (0.42) | SIGMAR1 | |
| SCHEMBL5841718 | 0.78 | SLC29A1 (0.44) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992085-B2 | Octahydro-2H-pyrido[1,2-a]pyrazine compounds | LES LABORATORIES SERVIER (FR) | 2006-01-31 | — | — | US | disclosed |
| EP-1275647-B1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-10-16 | — | — | US | disclosed |
| EP-1275647-A1 | Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195216-A1 | Octahydro-2H-pyrido[1,2-a] pyrazine compounds | CYP2W1, OXER1, IL1R1 | FGFR3 1782/4885KDR 3103/4885FGFR1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.